Castle Biosciences鈥� Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. The award recognizes CEOs who demonstrate exceptional leadership, vision and values in Houston's leading organizations.
The recognition highlights Maetzold's leadership in building Castle Biosciences into a company focused on developing innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma. The company's CFO Frank Stokes praised Maetzold's nearly two-decade tenure for creating a patient-centered culture and driving meaningful progress in personalized disease insights.
Castle Biosciences (Nasdaq: CSTL) ha annunciato che il suo fondatore, presidente e CEO Derek Maetzold 猫 stato nominato CEO pi霉 ammirato del 2025 dal Houston Business Journal. Il riconoscimento premia i CEO che dimostrano eccezionali capacit脿 di leadership, visione e valori nelle principali organizzazioni di Houston.
Questo premio mette in evidenza la leadership di Maetzold nel trasformare Castle Biosciences in un'azienda focalizzata sullo sviluppo di test diagnostici innovativi per tumori cutanei, esofago di Barrett e melanoma uveale. Il CFO dell鈥檃zienda, Frank Stokes, ha elogiato i quasi vent鈥檃nni di Maetzold per aver creato una cultura incentrata sul paziente e per aver guidato progressi significativi nelle diagnosi personalizzate delle malattie.
Castle Biosciences (Nasdaq: CSTL) anunci贸 que su fundador, presidente y CEO Derek Maetzold ha sido nombrado CEO M谩s Admirado 2025 por el Houston Business Journal. Este premio reconoce a los CEOs que demuestran liderazgo excepcional, visi贸n y valores en las principales organizaciones de Houston.
El reconocimiento destaca el liderazgo de Maetzold en la construcci贸n de Castle Biosciences como una empresa enfocada en desarrollar pruebas diagn贸sticas innovadoras para c谩nceres de piel, es贸fago de Barrett y melanoma uveal. El CFO de la compa帽铆a, Frank Stokes, elogi贸 la casi dos d茅cadas de Maetzold por crear una cultura centrada en el paciente y por impulsar avances significativos en el conocimiento personalizado de enfermedades.
Castle Biosciences (雮橃姢雼�: CSTL)電� 彀诫鞛愳澊鞛� 靷灔 瓴� CEO鞚� Derek Maetzold臧� 頊挫姢韯� 牍勳雼堨姢 鞝�雱愳澊 靹犾爼頃� 2025雲� 臧�鞛� 臁搓步氚涬姅 CEO鞐� 靹犾爼霅橃棃雼り碃 氚滍憸頄堨姷雼堧嫟. 鞚� 靸侅潃 頊挫姢韯挫潣 欤检殧 臁办鞐愳劀 韮侅洈頃� 毽崝鞁�, 牍勳爠 氚� 臧�旃橂ゼ 氤挫棳欷� CEO鞐愱矊 靾橃棳霅╇媹雼�.
鞚措矆 靾橃儊鞚� 頂茧秬鞎�, Barrett 鞁濍弰 氚� 韽弰毵� 頋戩儔膦� 歆勲嫧鞚� 鞙勴暅 順侅嫚鞝侅澑 瓴�靷� 臧滊皽鞐� 歆戩頃橂姅 Castle Biosciences毳� 甑稌頃� Maetzold鞚� 毽崝鞁潉 臧曥“頃╇媹雼�. 須岇偓鞚� CFO鞚� Frank Stokes電� Maetzold臧� 瓯办潣 20雲勳棎 瓯胳硱 頇橃瀽 欷戩嫭 氍疙檾毳� 臁办劚頃橁碃 臧滌澑 毵烄钉順� 歆堧硲 韱奠鞍霠レ棎靹� 鞚橂 鞛堧姅 歆勳爠鞚� 鞚措， 鞝愳潉 旃艾頄堨姷雼堧嫟.
Castle Biosciences (Nasdaq : CSTL) a annonc茅 que son fondateur, pr茅sident et PDG Derek Maetzold a 茅t茅 nomm茅 PDG le plus admir茅 de 2025 par le Houston Business Journal. Cette distinction r茅compense les PDG qui font preuve d'un leadership exceptionnel, de vision et de valeurs au sein des principales organisations de Houston.
Cette reconnaissance met en lumi猫re le leadership de Maetzold dans la transformation de Castle Biosciences en une entreprise ax茅e sur le d茅veloppement de tests diagnostiques innovants pour les cancers de la peau, l'艙sophage de Barrett et le m茅lanome uv茅al. Le directeur financier de l'entreprise, Frank Stokes, a salu茅 les pr猫s de deux d茅cennies de Maetzold pour avoir instaur茅 une culture centr茅e sur le patient et avoir fait progresser de mani猫re significative les connaissances personnalis茅es sur les maladies.
Castle Biosciences (Nasdaq: CSTL) gab bekannt, dass sein Gr眉nder, Pr盲sident und CEO Derek Maetzold vom Houston Business Journal als Most Admired CEO 2025 ausgezeichnet wurde. Die Auszeichnung ehrt CEOs, die au脽ergew枚hnliche F眉hrungskompetenz, Vision und Werte in den f眉hrenden Organisationen Houstons zeigen.
Die Anerkennung hebt Maetzolds F眉hrung hervor, Castle Biosciences zu einem Unternehmen aufzubauen, das sich auf die Entwicklung innovativer diagnostischer Tests f眉r Hautkrebs, Barrett-脰sophagus und Uvealmelanom konzentriert. Der CFO des Unternehmens, Frank Stokes, lobte Maetzolds fast zwanzigj盲hrige Amtszeit f眉r die Schaffung einer patientenorientierten Unternehmenskultur und den bedeutenden Fortschritt bei personalisierten Krankheitsanalysen.
- None.
- None.
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations
FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc.聽(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community.
鈥淒erek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,鈥� said Frank Stokes, chief financial officer of Castle Biosciences. 鈥淥ver nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress 鈥� building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.鈥�
鈥淚 am truly honored to receive this recognition from the Houston Business Journal,鈥� said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.鈥�
The award recipients will be honored at a special event held by the Houston Business Journal in August.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle鈥檚 current portfolio consists of tests for skin cancers, Barrett鈥檚 esophagus and uveal melanoma.聽Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit聽 and connect with us on聽,听,听 补苍诲听.鈥�
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
Media Contact:
Allison Marshall
Source: Castle Biosciences Inc.
Photos accompanying this announcement are available at:聽
FAQ
Who is Derek Maetzold and what award did he receive in 2025?
What diagnostic tests does Castle Biosciences (CSTL) develop?
How long has Derek Maetzold been leading Castle Biosciences (CSTL)?
When will the Houston Business Journal honor the Most Admired CEO award recipients?
